# Levosimendan In Ambulatory Heart Failure Patients

> **NCT04705337** · PHASE4 · TERMINATED · sponsor: **Medical University of Bialystok** · enrollment: 70 (actual)

## Conditions studied

- Heart Failure New York Heart Association Class III
- Heart Failure New York Heart Association Class IV
- Heart Failure, Systolic
- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** Levosimendan
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04705337
- **Lead sponsor:** Medical University of Bialystok
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-15
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-08-15
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** The level of recruitment, 62 participants enrolled, does not allow for achieving the protocol-defined target of 350 participants by the end of the recruitment period.
- **Last updated:** 2025-05-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04705337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04705337, "Levosimendan In Ambulatory Heart Failure Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04705337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*